Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study (Q42595535)

3 November 2017

title

Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study (English)

1 reference

3 November 2017

1 reference

8

Giovanni Passalacqua

1 reference

3 November 2017

Giorgio Walter Canonica

7

object named as

Giorgio W Canonica

1 reference

3 November 2017

Maurizio Marogna

1

1 reference

3 November 2017

Dante Tomassetti

2

1 reference

3 November 2017

Antonella Bernasconi

3

1 reference

3 November 2017

Fausto Colombo

4

1 reference

3 November 2017

Alessandro Massolo

5

1 reference

3 November 2017

Andrea Di Rienzo Businco

6

1 reference

3 November 2017

Salvatore Tripodi

9

1 reference

3 November 2017

publication date

1 August 2008

1 reference

Annals of Allergy, Asthma & Immunology

3 November 2017

published in

1 reference

3 November 2017

volume

101

1 reference

3 November 2017

issue

2

1 reference

3 November 2017

page(s)

206-211

1 reference

Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite.

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Safety of sublingual immunotherapy in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Safety of sublingual immunotherapy with a monomeric allergoid in very young children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Allergen-specific nasal challenge: response kinetics of clinical and inflammatory events to rechallenge

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Placebo effect in double-blind clinical trials: a review of interactions with medications

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: A long-term (13-year) retrospective study in real life

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960211-6

7 January 2021

10.1016/S1081-1206(10)60211-6

Identifiers

DOI

1 reference

3 November 2017

1 reference